115 related articles for article (PubMed ID: 11478395)
1. The search for novel adjuvants for early life vaccinations: can "danger" motifs show us the way?
Kovarik J; Siegrist CA
Arch Immunol Ther Exp (Warsz); 2001; 49(3):209-15. PubMed ID: 11478395
[TBL] [Abstract][Full Text] [Related]
2. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
3. Activation of murine macrophages by Neisseria meningitidis and IFN-gamma in vitro: distinct roles of class A scavenger and Toll-like pattern recognition receptors in selective modulation of surface phenotype.
Mukhopadhyay S; Peiser L; Gordon S
J Leukoc Biol; 2004 Sep; 76(3):577-84. PubMed ID: 15218052
[TBL] [Abstract][Full Text] [Related]
4. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
[TBL] [Abstract][Full Text] [Related]
5. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.
Ahmad-Nejad P; Häcker H; Rutz M; Bauer S; Vabulas RM; Wagner H
Eur J Immunol; 2002 Jul; 32(7):1958-68. PubMed ID: 12115616
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
7. Two receptor theory in innate immune activation: studies on the receptors for bacillus Culmet Guillen-cell wall skeleton.
Seya T; Matsumoto M; Tsuji S; Begum NA; Nomura M; Azuma I; Hayashi A; Toyoshima K
Arch Immunol Ther Exp (Warsz); 2001; 49 Suppl 1():S13-21. PubMed ID: 11603865
[TBL] [Abstract][Full Text] [Related]
8. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
Zimmermann S; Dalpke A; Heeg K
Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
[TBL] [Abstract][Full Text] [Related]
9. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions.
Lang R; Schoenen H; Desel C
Immunobiology; 2011 Nov; 216(11):1184-91. PubMed ID: 21742403
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor signaling in anti-cancer immunity.
Okamoto M; Sato M
J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564
[TBL] [Abstract][Full Text] [Related]
11. Modulating vaccine responses with dendritic cells and Toll-like receptors.
Pulendran B
Immunol Rev; 2004 Jun; 199():227-50. PubMed ID: 15233738
[TBL] [Abstract][Full Text] [Related]
12. The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity.
Fraser IP; Koziel H; Ezekowitz RA
Semin Immunol; 1998 Oct; 10(5):363-72. PubMed ID: 9799711
[TBL] [Abstract][Full Text] [Related]
13. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
14. Adjuvants and autoimmunity.
Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
[TBL] [Abstract][Full Text] [Related]
15. The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans.
Ferwerda G; Netea MG; Joosten LA; van der Meer JW; Romani L; Kullberg BJ
Vaccine; 2010 Jan; 28(3):614-22. PubMed ID: 19887129
[TBL] [Abstract][Full Text] [Related]
16. Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs.
Jo EK
Curr Opin Infect Dis; 2008 Jun; 21(3):279-86. PubMed ID: 18448973
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant properties of CpG oligonucleotides in primates.
Verthelyi D
Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptors control activation of adaptive immune responses.
Schnare M; Barton GM; Holt AC; Takeda K; Akira S; Medzhitov R
Nat Immunol; 2001 Oct; 2(10):947-50. PubMed ID: 11547333
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors: networking for success.
Underhill DM
Eur J Immunol; 2003 Jul; 33(7):1767-75. PubMed ID: 12811836
[TBL] [Abstract][Full Text] [Related]
20. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
Chaung HC
Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
